ClinicalTrials.gg
Active, not recruitingNCT06843239Updated Jul 20, 2026

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

A Phase 2 interventional study of Tibulizumab and Placebo in Systemic Sclerosis (SSc) and Scleroderma, sponsored by Zura Bio Inc. Active, not recruiting at 60 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Zura Bio Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Scleroderma, Systemic with a site in Argentina — 4 open to participants now, 6 under way, 3 of them phase 3. Scleroderma, Systemic · Argentina.

Planned enrollment
10th of 13
80 · median 174
Started
2025
the only one that year
Phase 2
6 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Scleroderma, Systemic with a site in Argentina, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, and was the 12th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

4 of the 14 studies in Scleroderma, Systemic with a site in Argentina are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Scleroderma, Systemic with a site in Argentina, or all of them as a file.
02

Study summary

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

03

Conditions studied

  • Systemic Sclerosis (SSc)
  • Scleroderma

Keywords

  • Scleroderma
  • Systemic Sclerosis (SSc)
  • Tibulizumab
  • Cutaneous
  • Interstitial lung disease (ILD)
  • Autoimmune diseases
  • Immune system diseases
  • Systemic Sclerosis interstitial lung disease (SSC-ILD)
  • Skin Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 75 years of age
  • between 18.0 and 38.0 kg/m²
  • Fulfills classification criteria for SSc according to ACR/EULAR 2013 criteria
  • Has diffuse cutaneous SSc, defined as mRSS >0 over at least one skin area proximal to the elbows and/or knees, in addition to acral fibrosis
  • Has had SSc (defined as the first non-Raynaud's phenomenon (RP) symptom or sign attributed to SSc) for ≤7 years
  • mRSS ≥15 and ≤45 at screening. Additional requirements for participants ≥2 years to ≤7 years from SSc onset and RNA Polymerase III antibody positive
  • FVC >50% predicted
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥40% predicted (corrected for )

Exclusion criteria

Exclusion Criteria:

  • Has any of the following complications:

    • Left ventricular failure
    • Pulmonary arterial hypertension
    • Renal crisis within previous 6 months
    • Gastrointestinal dysmotility within previous 3 months
    • Digital ischemia with gangrene, amputation, or unscheduled hospitalization within previous 3 months
  • Current rheumatic disease other than SSc that could interfere with assessment of SSc
  • Lung disease requiring continuous oxygen therapy
  • Evidence or suspicion of active or latent tuberculosis
  • Active Crohn's Disease or ulcerative colitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Tibulizumab

    Subcutaneous injection

    Biological: Tibulizumab

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Biological: Tibulizumab · Other: Placebo

Interventions

  • BiologicalTibulizumab

    Anti BAFF/IL-17 antibody

    Also known as: ZB-106

  • OtherPlacebo

    Placebo (inactive)

    Also known as: ZB-106 placebo

06

What researchers measure

Primary outcomes

  1. [Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks

    The mRSS assesses skin thickness at 17 different cutaneous sites across the body using a scale from 0 (normal skin) to 3 (severe thickening), with a total score ranging from 0 (no thickening) to 51 (severe thickening in all 17 areas)

    Time frame: Week 24

  2. [Period 2] Safety and tolerability of tibulizumab

    Assessed by the incidence of all treatment-emergent adverse events (TEAEs), as well as changes from baseline in vital signs, electrocardiogram (ECG) parameters, and laboratory results

    Time frame: Week 52

Secondary outcomes

  1. [Period 1] Change from baseline in quantitative interstitial lung disease (QILD) obtained with high-resolution quantitative tomography (HRCT) in the whole lung in participants with SSc-interstitial lung disease (ILD)

    HRCT measures the extent of interstitial lung disease by quantifying the amount of lung fibrosis, ground-glass opacity, and honeycomb lung, which are used to calculate the QILD score (scores can range from 0 to 100%, with higher scores indicating greater disease extent)

    Time frame: Week 24

  2. [Period 1] Change from baseline in forced vital capacity (FVC) in participants with SSc-ILD

    FVC is the amount of air that can be forcibly exhaled after the deepest possible breath

    Time frame: Week 24

  3. [Period 1] Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    HAQ-DI evaluates patients' self-assessed degree of disability across eight categories, with scores ranging from 0 to 3, where 3 indicates the worst degree of disability

    Time frame: Week 24

  4. [Period 1] Safety and tolerability of tibulizumab

    Assessed by the incidence of all TEAEs, as well as changes from baseline in vital signs, ECG parameters, and laboratory results

    Time frame: Week 24

  5. [Period 2] Change from baseline in mRSS

    The mRSS assesses skin thickness at 17 different cutaneous sites across the body using a scale from 0 (normal skin) to 3 (severe thickening), with a total score ranging from 0 (no thickening) to 51 (severe thickening in all 17 areas)

    Time frame: Week 52

  6. [Period 2] Change from baseline in QILD obtained with HRCT in the whole lung in participants with SSc-ILD

    HRCT measures the extent of interstitial lung disease by quantifying the amount of lung fibrosis, ground-glass opacity, and honeycomb lung, which are used to calculate the QILD score (scores can range from 0 to 100%, with higher scores indicating greater disease extent)

    Time frame: Week 52

07

Study locations

60 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 24, 2025
StartActual
Feb 6, 2025
Primary completionEst.
May 2027
CompletionEst.
Jan 2028
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843239
Lead sponsor
Zura Bio Inc
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Feb 6, 2025
Primary completion
May 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 20, 2026

Study contacts

Study Director
study director · Zura Bio Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tibulizumab

Start the discussion